After two days of making his case to Senate committees, Robert F. Kennedy Jr.’s bid to lead federal health agencies still ...

The FDA has approved Ozempic (semaglutide) to reduce the risk of kidney disease worsening and cardiovascular death in those with T2D and CKD.

Currently, Rilparencel’s Phase 3 is planned to deliver full data by Q3 2027 if no surrogate endpoint is found that’s suitable ...

Chronic kidney disease (CKD) is a growing global health concern, significantly contributing to morbidity and mortality rates worldwide. Characterized by a ...

The FDA has accepted for review the NDA for bumetanide nasal spray for edema associated with CHF, as well as hepatic and renal disease.

The Food and Drug Administration on Thursday approved a new type of nonopioid painkiller from Vertex Pharmaceuticals, NBC ...

HonorHealth announced the creation of its new international Center for Translational Science. Sanofi said it will repurchase $5.2 billion of stock and grow profits faster this year as the drugmaker ...

The U.S. will ban nearly all uses of the common industrial cleaning agent, trichloroethylene (TCE), this year—more than 50 ...

The FDA’s approval of Ozempic to battle chronic kidney disease “allows us to more broadly address conditions within cardiovascular-kidney-metabolic syndrome, which affects millions of ...

The FDA has approved popular antiobesity drug Ozempic to help protect patients with type 2 diabetes from kidney disease.

The FDA has approved Ozempic to reduce kidney failure risk in people with type 2 diabetes and chronic kidney disease. Studies ...